Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head Injuries, Penetrating | 8 | 2025 | 64 | 1.900 |
Why?
|
| Wounds, Gunshot | 4 | 2025 | 111 | 1.080 |
Why?
|
| Craniotomy | 2 | 2020 | 89 | 0.800 |
Why?
|
| tau Proteins | 6 | 2009 | 78 | 0.750 |
Why?
|
| Papilloma, Inverted | 1 | 2020 | 6 | 0.690 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2020 | 24 | 0.680 |
Why?
|
| Fasciitis | 1 | 2019 | 9 | 0.660 |
Why?
|
| Brain Neoplasms | 6 | 2016 | 799 | 0.660 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2020 | 106 | 0.650 |
Why?
|
| Orbital Diseases | 1 | 2019 | 17 | 0.650 |
Why?
|
| Brain Diseases | 1 | 2019 | 189 | 0.590 |
Why?
|
| Neurosurgical Procedures | 5 | 2023 | 307 | 0.550 |
Why?
|
| Glioma | 3 | 2016 | 303 | 0.530 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2018 | 89 | 0.520 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2016 | 17 | 0.510 |
Why?
|
| Meningitis | 1 | 2016 | 22 | 0.510 |
Why?
|
| Pituitary Neoplasms | 3 | 2024 | 71 | 0.460 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 188 | 0.460 |
Why?
|
| Streptavidin | 1 | 2013 | 14 | 0.420 |
Why?
|
| Antigens, CD20 | 1 | 2013 | 35 | 0.420 |
Why?
|
| Ferric Compounds | 1 | 2013 | 40 | 0.410 |
Why?
|
| Brain | 5 | 2025 | 2345 | 0.400 |
Why?
|
| Endoscopy | 1 | 2016 | 362 | 0.390 |
Why?
|
| Lymphoma, B-Cell | 1 | 2013 | 109 | 0.380 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 567 | 0.360 |
Why?
|
| Antibodies | 1 | 2013 | 354 | 0.360 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2022 | 111 | 0.320 |
Why?
|
| Biopsy | 1 | 2013 | 1197 | 0.310 |
Why?
|
| Otolaryngology | 2 | 2022 | 55 | 0.310 |
Why?
|
| Neurofibrillary Tangles | 3 | 2008 | 46 | 0.310 |
Why?
|
| Protein Processing, Post-Translational | 4 | 2008 | 408 | 0.310 |
Why?
|
| Peptide Fragments | 2 | 2006 | 466 | 0.280 |
Why?
|
| Alzheimer Disease | 4 | 2008 | 522 | 0.270 |
Why?
|
| Office Visits | 2 | 2024 | 50 | 0.260 |
Why?
|
| Skull Base | 4 | 2022 | 48 | 0.260 |
Why?
|
| Humans | 33 | 2025 | 92202 | 0.250 |
Why?
|
| Postoperative Complications | 1 | 2016 | 2438 | 0.230 |
Why?
|
| Caspases | 1 | 2004 | 158 | 0.220 |
Why?
|
| Meningioma | 2 | 2016 | 65 | 0.220 |
Why?
|
| Neuroimaging | 1 | 2025 | 127 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2025 | 2687 | 0.190 |
Why?
|
| Adenoma | 1 | 2024 | 255 | 0.190 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 512 | 0.190 |
Why?
|
| Ambulatory Care Facilities | 1 | 2022 | 112 | 0.190 |
Why?
|
| Patient Satisfaction | 2 | 2022 | 498 | 0.180 |
Why?
|
| Gene Rearrangement | 2 | 2019 | 176 | 0.180 |
Why?
|
| Brain Injuries | 1 | 2023 | 169 | 0.170 |
Why?
|
| Socioeconomic Factors | 1 | 2023 | 610 | 0.170 |
Why?
|
| Injury Severity Score | 1 | 2021 | 151 | 0.170 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 67 | 0.170 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2023 | 251 | 0.170 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2019 | 23 | 0.160 |
Why?
|
| Gene Fusion | 1 | 2019 | 40 | 0.160 |
Why?
|
| Myosin Heavy Chains | 1 | 2019 | 91 | 0.160 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 65 | 0.160 |
Why?
|
| Drainage | 1 | 2020 | 170 | 0.160 |
Why?
|
| Intracranial Hemorrhages | 1 | 2020 | 132 | 0.160 |
Why?
|
| Cranial Fossa, Middle | 1 | 2018 | 12 | 0.150 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2018 | 28 | 0.150 |
Why?
|
| Telemedicine | 1 | 2021 | 211 | 0.150 |
Why?
|
| Middle Aged | 7 | 2025 | 27021 | 0.150 |
Why?
|
| Male | 11 | 2025 | 43833 | 0.150 |
Why?
|
| Skull | 1 | 2020 | 260 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 1148 | 0.140 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 376 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 3486 | 0.140 |
Why?
|
| Seizures | 1 | 2020 | 311 | 0.140 |
Why?
|
| Chromosomes, Human | 1 | 2016 | 65 | 0.130 |
Why?
|
| Professional Corporations | 1 | 2016 | 1 | 0.130 |
Why?
|
| Oncogene Proteins v-myb | 1 | 2016 | 3 | 0.130 |
Why?
|
| Lymphoma | 1 | 2018 | 267 | 0.130 |
Why?
|
| Cranial Nerve Diseases | 1 | 2016 | 8 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2013 | 679 | 0.120 |
Why?
|
| Nose | 1 | 2016 | 94 | 0.120 |
Why?
|
| Meningeal Neoplasms | 1 | 2016 | 70 | 0.120 |
Why?
|
| Child | 4 | 2022 | 7312 | 0.120 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2016 | 132 | 0.120 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 129 | 0.110 |
Why?
|
| Precision Medicine | 2 | 2016 | 424 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 284 | 0.100 |
Why?
|
| Glasgow Coma Scale | 2 | 2023 | 81 | 0.100 |
Why?
|
| Tissue Engineering | 1 | 2015 | 200 | 0.100 |
Why?
|
| Adult | 7 | 2025 | 27505 | 0.100 |
Why?
|
| Female | 9 | 2025 | 47808 | 0.100 |
Why?
|
| Watchful Waiting | 1 | 2013 | 69 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 136 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2025 | 9629 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 364 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 529 | 0.090 |
Why?
|
| Trans-Activators | 1 | 2013 | 443 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 807 | 0.080 |
Why?
|
| Amino Acid Sequence | 3 | 2009 | 2082 | 0.080 |
Why?
|
| Mutation | 6 | 2016 | 4220 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2021 | 2972 | 0.080 |
Why?
|
| Antibody Specificity | 2 | 2008 | 130 | 0.080 |
Why?
|
| Gliosis | 1 | 2008 | 34 | 0.080 |
Why?
|
| Nitrates | 1 | 2008 | 36 | 0.070 |
Why?
|
| Protein Folding | 1 | 2009 | 293 | 0.070 |
Why?
|
| Astrocytes | 1 | 2008 | 144 | 0.070 |
Why?
|
| Aminopeptidases | 1 | 2006 | 14 | 0.070 |
Why?
|
| Epitopes | 2 | 2004 | 255 | 0.070 |
Why?
|
| Arachidonic Acid | 1 | 2006 | 63 | 0.070 |
Why?
|
| Young Adult | 3 | 2025 | 6600 | 0.070 |
Why?
|
| Algorithms | 1 | 2015 | 1943 | 0.070 |
Why?
|
| Protein Conformation | 2 | 2006 | 905 | 0.070 |
Why?
|
| Aged | 5 | 2025 | 19928 | 0.070 |
Why?
|
| Disease Progression | 2 | 2015 | 1504 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2006 | 1020 | 0.060 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 3035 | 0.060 |
Why?
|
| Exome | 2 | 2016 | 132 | 0.060 |
Why?
|
| Caspase 6 | 1 | 2004 | 3 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2004 | 23 | 0.060 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2016 | 39 | 0.060 |
Why?
|
| src-Family Kinases | 1 | 2004 | 76 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2004 | 153 | 0.060 |
Why?
|
| Current Procedural Terminology | 1 | 2024 | 12 | 0.060 |
Why?
|
| Kinetics | 1 | 2006 | 1550 | 0.050 |
Why?
|
| Binding Sites | 1 | 2006 | 1132 | 0.050 |
Why?
|
| Neurotoxins | 1 | 2003 | 49 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 2366 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 339 | 0.050 |
Why?
|
| Temporal Lobe | 1 | 2004 | 184 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 442 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 6914 | 0.050 |
Why?
|
| Comparative Effectiveness Research | 1 | 2023 | 54 | 0.050 |
Why?
|
| Intracranial Pressure | 1 | 2023 | 90 | 0.050 |
Why?
|
| Death | 1 | 2023 | 92 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2006 | 1337 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2003 | 214 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2025 | 441 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 1407 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 495 | 0.050 |
Why?
|
| Receptors, Drug | 1 | 2001 | 54 | 0.050 |
Why?
|
| Resuscitation | 1 | 2022 | 111 | 0.050 |
Why?
|
| Pheochromocytoma | 1 | 2001 | 49 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2023 | 267 | 0.050 |
Why?
|
| Adolescent | 2 | 2025 | 9491 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2023 | 292 | 0.050 |
Why?
|
| Patient Participation | 1 | 2023 | 229 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 229 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2001 | 267 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1311 | 0.040 |
Why?
|
| Neoplasms | 1 | 2015 | 3123 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2023 | 426 | 0.040 |
Why?
|
| Spinal Injuries | 1 | 2020 | 27 | 0.040 |
Why?
|
| Length of Stay | 1 | 2023 | 796 | 0.040 |
Why?
|
| Hematologic Diseases | 1 | 2020 | 78 | 0.040 |
Why?
|
| Craniocerebral Trauma | 1 | 2020 | 57 | 0.040 |
Why?
|
| Survivors | 1 | 2020 | 198 | 0.040 |
Why?
|
| Patient Selection | 1 | 2023 | 689 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2020 | 82 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2020 | 119 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 2667 | 0.040 |
Why?
|
| Intracranial Aneurysm | 1 | 2020 | 195 | 0.040 |
Why?
|
| Apoptosis | 1 | 2004 | 1752 | 0.040 |
Why?
|
| Steroids | 1 | 2018 | 173 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2016 | 32 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 3766 | 0.030 |
Why?
|
| Neurons | 1 | 2004 | 1605 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 183 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 68 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1652 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2015 | 146 | 0.030 |
Why?
|
| Time Factors | 1 | 2024 | 5427 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 101 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 375 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 105 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1835 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2016 | 222 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 532 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 2013 | 98 | 0.030 |
Why?
|
| Smoothened Receptor | 1 | 2013 | 6 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 290 | 0.030 |
Why?
|
| Enzyme Activation | 2 | 2006 | 700 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 899 | 0.030 |
Why?
|
| Neurofibromin 2 | 1 | 2013 | 29 | 0.030 |
Why?
|
| PC12 Cells | 2 | 2003 | 115 | 0.030 |
Why?
|
| Multigene Family | 1 | 2013 | 203 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 2360 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 4459 | 0.020 |
Why?
|
| Machine Learning | 1 | 2015 | 292 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 620 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2015 | 553 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2004 | 799 | 0.020 |
Why?
|
| Genome, Human | 1 | 2016 | 797 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 743 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2013 | 829 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1762 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 874 | 0.020 |
Why?
|
| Alleles | 1 | 2013 | 1140 | 0.020 |
Why?
|
| Base Sequence | 1 | 2013 | 2332 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1475 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2009 | 283 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2015 | 1392 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2009 | 215 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2008 | 58 | 0.020 |
Why?
|
| Tyrosine | 1 | 2008 | 133 | 0.020 |
Why?
|
| Plaque, Amyloid | 1 | 2008 | 61 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2015 | 1721 | 0.020 |
Why?
|
| Puromycin | 1 | 2006 | 10 | 0.020 |
Why?
|
| Genomics | 1 | 2013 | 804 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2020 | 8698 | 0.020 |
Why?
|
| Rats | 2 | 2003 | 4069 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 3809 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2004 | 8 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 2004 | 64 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2015 | 3509 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 324 | 0.010 |
Why?
|
| Nitroblue Tetrazolium | 1 | 2003 | 2 | 0.010 |
Why?
|
| Ginkgo biloba | 1 | 2003 | 7 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1808 | 0.010 |
Why?
|
| Diffusion | 1 | 2003 | 91 | 0.010 |
Why?
|
| Antigens | 1 | 2004 | 229 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2004 | 351 | 0.010 |
Why?
|
| Body Temperature | 1 | 2003 | 127 | 0.010 |
Why?
|
| Animals | 3 | 2013 | 28055 | 0.010 |
Why?
|
| Neuroprotective Agents | 1 | 2003 | 97 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 456 | 0.010 |
Why?
|
| Imidazoline Receptors | 1 | 2001 | 2 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2004 | 1140 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2001 | 33 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2001 | 111 | 0.010 |
Why?
|
| Clonidine | 1 | 2001 | 33 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2001 | 137 | 0.010 |
Why?
|
| Plant Extracts | 1 | 2003 | 245 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2001 | 112 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 1011 | 0.010 |
Why?
|
| Imidazoles | 1 | 2001 | 141 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2001 | 277 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 699 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 12162 | 0.010 |
Why?
|
| Models, Biological | 1 | 2004 | 1784 | 0.010 |
Why?
|